Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer - A retrospective study

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Vinayagam, Raman ^a,b,c   Sibson, D Ross ^a,b   Holcombe, Christopher ^c   Aachi, Vijay ^c   Davies, Michael P A ^a,b  

^a CLATTERBRIDGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 2; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; POSTTRANSCRIPTIONAL GENE SILENCING; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; COMPARATIVE STUDY; GENETICS; METHODOLOGY; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34548186909     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-131     Document Type: Article

References (25)

1. Clarke R Liu MC Bouker KB Gu Z Lee RY Zhu Y Skaar TC Gomez B O'Brien K Wang Y Hilakivi-Clarke LA Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 2003 22 47 7316-7339 10.1038/sj.onc.1206937 14576841
2. Shao W Brown M Advances in estrogen receptor biology: Prospects for improvements in targeted breast cancer therapy Breast Cancer Res 2004 6 1 39-52 314456 14680484 10.1186/bcr742
3. Poola I Molecular assays to profile 10 estrogen receptor Beta isoform mRNA copy numbers in ovary, breast, uterus, and bone tissues Endocrine 2003 22 2 101-112 10.1385/ENDO:22:2:101 14665713
4. Miller WR Anderson TJ Dixon JM Saunders PT Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: Prediction of response and effects of treatment Br J Cancer 2006 94 9 1333-1338 10.1038/sj.bjc.6603082 16622466
5. Hall JM McDonnell DP The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens Endocrinology 1999 140 12 5566-5578 10.1210/en.140.12.5566 10579320
6. Speirs V Oestrogen receptor beta in breast cancer: Good, bad or still too early to tell? J Pathol 2002 197 2 143-147 10.1002/path.1072 12015736
7. Esslimani-Sahla M Simony-Lafontaine J Kramar A Lavaill R Mollevi C Warner M Gustafsson JA Rochefort H Estrogen Receptor {beta} (ER{beta}) Level but Not Its ER{beta}cx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer Clin Cancer Res 2004 10 17 5769-5776 10.1158/ 1078-0432.CCR-04-0389 15355905
8. Herynk MH Fuqua SA Estrogen receptor mutations in human disease Endocr Rev 2004 25 6 869-898 10.1210/er.2003-0010 15583021
9. O'Neill PA Davies MP Shaaban AM Innes H Torevell A Sibson DR Foster CS Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers Br J Cancer 2004 91 9 1694-1702 15477865
10. Palmieri C Lam EW Mansi J MacDonald C Shousha S Madden P Omoto Y Sunters A Warner M Gustafsson JA Coombes RC The Expression of ERbetacx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival Clin Cancer Res 2004 10 7 2421-2428 10.1158/1078-0432.CCR-03-0215 15073120
11. Paruthiyil S Parmar H Kerekatte V Cunha GR Firestone GL Leitman DC Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest Cancer Res 2004 64 1 423-428 10.1158/0008-5472.CAN-03-2446 14729654
12. Saji S Hirose M Toi M Clinical significance of estrogen receptor beta in breast cancer Cancer Chemother Pharmacol 2005 1-6
13. Murphy LC Watson PH Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 2006 13 2 327-334 10.1677/erc.1.01141 16728566
14. Ogawa S Inoue S Watanabe T Orimo A Hosoi T Ouchi Y Muramatsu M Molecular cloning and characterization of human estrogen receptor betacx: A potential inhibitor of estrogen action in human Nucleic Acids Res 1998 26 15 3505-3512 147730 9671811 10.1093/nar/26.15.3505
15. Leung YK Mak P Hassan S Ho SM Estrogen receptor (ER)-beta isoforms: A key to understanding ER-beta signaling Proc Natl Acad Sci U S A 2006 103 35 13162-13167 1552044 16938840 10.1073/pnas.0605676103
16. Poola I Abraham J Baldwin K Saunders A Bhatnagar R Estrogen Receptors Beta4 and Beta5 Are Full Length Functionally Distinct ERbeta Isoforms: Cloning from Human Ovary and Functional Characterization Endocrine 2005 27 3 227-238 10.1385/ENDO:27:3:227 16230778
17. Davies MP O'Neill PA Innes H Sibson DR Prime W Holcombe C Foster CS Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer J Mol Endocrinol 2004 33 3 773-782 10.1677/jme.1.01574 15591034
18. Saunders PT Millar MR Macpherson S Irvine DS Groome NP Evans LR Sharpe RM Scobie GA ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in distinct cell populations in the adult human testis J Clin Endocrinol Metab 2002 87 6 2706-2715 10.1210/jc.87.6.2706 12050238
19. Harvey JM Clark GM Osborne CK Allred DC Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 1999 17 5 1474-1481 10334533
20. Dupont WD Plummer WD Jr. Power and sample size calculations for studies involving linear regression Control Clin Trials 1998 19 6 589-601 10.1016/S0197-2456(98)00037-3 9875838
21. Schoenfeld DA Richter JR Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint Biometrics 1982 38 1 163-170 10.2307/2530299 7082758
22. Leygue E Dotzlaw H Watson PH Murphy LC Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue Cancer Research 1999 59 6 1175-1179 10096542
23. Iwao K Miyoshi Y Egawa C Ikeda N Noguchi S Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers Int J Cancer 2000 88 5 733-736 10.1002/ 1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M 11072241
24. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner FL Walker MG Watson D Park T Hiller W Fisher ER Wickerham DL Bryant J Wolmark N A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004 351 27 2817-2826 10.1056/NEJMoa041588 15591335
25. Critchley HO Henderson TA Kelly RW Scobie GS Evans LR Groome NP Saunders PT Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle J Clin Endocrinol Metab 2002 87 11 5265-5273 10.1210/jc.2002-020502 12414901